Making a
Meaningful Difference
Zymeworks is a publicly listed (NASDAQ: ZYME) Zymeworks is a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases. Zymeworks’ complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates
Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026
Investigational new drug (IND) applications for initiating first-in-human studies for ZW220 and ZW251 in solid tumors anticipated in 2025 IND applications for initiating first-in-human studies for ZW209 and ZW1528 anticipated in 2026 Phase 3 HERIZON-GEA-01 top-line results for Ziihera®
01.08.2025
Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases
Company on track to deliver five Investigational New Drug (IND) applications as part of ‘5 by 5’ solid tumor strategy 18 months ahead of original target Nomination of ZW209, a novel trispecific T cell engager, as fifth development candidate in the Company’s solid tumor portfolio Expansion into
12.12.2024
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia , Nov. 21, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that
11.21.2024Press Releases
Read the latest news and updates from Zymeworks Inc.